Biocon

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE376G01013
  • NSEID: BIOCON
  • BSEID: 532523
INR
413.70
2 (0.49%)
BSENSE

Jun 18

BSE+NSE Vol: 16.91 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Anthem Bioscienc
Ipca Labs
Biocon
Glenmark Pharma
Laurus Labs
Dr Reddy's Labs
Abbott India
Lupin
Mankind Pharma
Aurobindo Pharma
Alkem Lab
Why is Biocon Ltd. ?
1
The company has declared positive results in Dec'2025 after 2 consecutive negative quarters
  • CASH AND CASH EQUIVALENTS(HY) Highest at Rs 4,601.10 cr
  • DEBT-EQUITY RATIO(HY) Lowest at 0.62 times
  • PAT(Q) Highest at Rs 437.20 cr.
2
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 20-May-26 and has generated -4.58% returns since then
  • The stocks MACD and KST technical factors are also Bullish
3
With ROCE of 3.2, it has a Attractive valuation with a 1.7 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 20.85%, its profits have fallen by -21.1%
4
Rising Promoter Confidence
  • Promoters have increased their stake in the company by 14.5% over the previous quarter and currently hold 44.91% of the company
  • Promoters increasing their stake is a sign of high confidence in the future of the business
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Biocon should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Biocon for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Biocon
20.91%
0.69
30.35%
Sensex
-4.95%
-0.37
13.26%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
18.83%
EBIT Growth (5y)
9.87%
EBIT to Interest (avg)
4.90
Debt to EBITDA (avg)
4.70
Net Debt to Equity (avg)
0.34
Sales to Capital Employed (avg)
0.43
Tax Ratio
17.66%
Dividend Payout Ratio
5.92%
Pledged Shares
0
Institutional Holding
31.59%
ROCE (avg)
5.98%
ROE (avg)
4.94%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
89
Industry P/E
34
Price to Book Value
1.96
EV to EBIT
52.82
EV to EBITDA
22.76
EV to Capital Employed
1.72
EV to Sales
4.62
PEG Ratio
NA
Dividend Yield
0.10%
ROCE (Latest)
3.25%
ROE (Latest)
2.21%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 4,601.10 cr

DEBT-EQUITY RATIO(HY)

Lowest at 0.62 times

PAT(Q)

Highest at Rs 437.20 cr.

-6What is not working for the Company
PBT LESS OI(Q)

At Rs 108.30 cr has Fallen at -32.3% (vs previous 4Q average

ROCE(HY)

Lowest at 4.31%

NON-OPERATING INCOME(Q)

is 51.99 % of Profit Before Tax (PBT

Loading Valuation Snapshot...
Here's what is working for Biocon
Profit After Tax (PAT) - Quarterly
At Rs 437.20 cr has Grown at 275.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 116.51 Cr
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 437.20 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Cash and Cash Equivalents - Half Yearly
Highest at Rs 4,601.10 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio - Half Yearly
Lowest at 0.62 times
in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Biocon
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 108.30 cr has Fallen at -32.3% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 159.98 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Non Operating Income - Quarterly
is 51.99 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT

Non Operating Income - Quarterly
Highest at Rs 117.30 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income